Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement (PGEN)
· seekingalpha.com
Precigen stock is upgraded to Strong Buy as PAPZIMEOS revenues are up after FDA approval for RRP. Learn PGEN's Q2 profitability, catalysts, and EMA upside.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...